4D Molecular Therapeutics Inc
(FDMT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 0 | 0 | 0 | 49,652 |
| Receivables | 0 | 0 | 0 | 978 |
| Other current assets | 0 | 0 | 0 | 1,878 |
| TOTAL | $0 | $0 | $0 | $52,508 |
| Non-Current Assets | ||||
| PPE Net | N/A | N/A | N/A | 7,674 |
| Other Non-Current Assets | 0 | 0 | 0 | 677 |
| TOTAL | $N/A | $N/A | $N/A | $8,351 |
| Total Assets | $0 | $0 | $0 | $58,234 |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 0 | 0 | 0 | 1,744 |
| Accrued Expenses | 0 | 0 | 0 | 5,347 |
| Other current liabilities | 0 | 0 | 0 | 5,864 |
| TOTAL | $0 | $0 | $0 | $12,955 |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 104,646 |
| TOTAL | $N/A | $N/A | $N/A | $118,249 |
| Total Liabilities | $0 | $0 | $0 | $131,204 |
| Shareholders' Equity | ||||
| Common Shares | 0 | 0 | 0 | 1 |
| Retained earnings | 0 | 0 | 0 | -79,025 |
| TOTAL | $0 | $0 | $0 | $-72,970 |
| Total Liabilities And Equity | $0 | $0 | $0 | $58,234 |